What is lecanemab, the newly approved Alzheimer’s drug? Can it really slow down dementia?

The drug may slow the progression of Alzheimer’s disease, but it doesn’t improve the symptoms. It’s also incredibly expensive ...

Google DORA Research: Software Developers Use AI ‘Heavily’

Google’s State of AI-assisted Software Development Report 2025 reveals AI adoption increased, but trust in AI is still uneven ...

OpenAI Expands Stargate With Five New Data Centers Across the US

OpenAI is building five more data centers in the United States as part of the Stargate project. These will be located in ...
Opinion
Digital InsuranceOpinion

Data governance is an insurance growth engine

Enterprise data governance is the foundation for safe, scalable AI that transforms underwriting, claims, and distribution.

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of ...

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher ...